Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan 3;1(1):CD011093.
doi: 10.1002/14651858.CD011093.pub2.

Fulvestrant for hormone-sensitive metastatic breast cancer

Clara I Lee  1   2 , Annabel Goodwin  3   4   5 , Nicholas Wilcken  1   2
Affiliations
Meta-Analysis

Fulvestrant for hormone-sensitive metastatic breast cancer

Clara I Lee et al. Cochrane Database Syst Rev. .

Abstract

Background: Fulvestrant is a selective oestrogen receptor down-regulator (SERD), which by blocking proliferation of breast cancer cells, is an effective endocrine treatment for women with hormone-sensitive advanced breast cancer. The goal of such systemic therapy in this setting is to reduce symptoms, improve quality of life, and increase survival time.

Objectives: To assess the efficacy and safety of fulvestrant for hormone-sensitive locally advanced or metastatic breast cancer in postmenopausal women, as compared to other standard endocrine agents.

Search methods: We searched the Cochrane Breast Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 7 July 2015. We also searched major conference proceedings (American Society of Clinical Oncology (ASCO) and San Antonio Breast Cancer Symposium) and practice guidelines from major oncology groups (ASCO, European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network, and Cancer Care Ontario). We handsearched reference lists from relevant studies.

Selection criteria: We included for analyses randomised controlled trials that enrolled postmenopausal women with hormone-sensitive advanced breast cancer (TNM classifications: stages IIIA, IIIB, and IIIC) or metastatic breast cancer (TNM classification: stage IV) with an intervention group treated with fulvestrant with or without other standard anticancer therapy.

Data collection and analysis: Two review authors independently extracted data from trials identified in the searches, conducted 'Risk of bias' assessments of the included studies, and assessed the overall quality of the evidence using the GRADE approach. Outcome data extracted from these trials for our analyses and review included progression-free survival (PFS) or time to progression (TTP) or time to treatment failure, overall survival, clinical benefit rate, toxicity, and quality of life. We used the fixed-effect model for meta-analysis where possible.

Main results: We included nine studies randomising 4514 women for meta-analysis and review. Overall results for the primary endpoint of PFS indicated that women receiving fulvestrant did at least as well as the control groups (hazard ratio (HR) 0.95, 95% confidence interval (CI) 0.89 to 1.02; P = 0.18, I2= 56%, 4258 women, 9 studies, high-quality evidence). In the one high-quality study that tested fulvestrant at the currently approved and now standard dose of 500 mg against anastrozole, women treated with fulvestrant 500 mg did better than anastrozole, with a HR for TTP of 0.66 (95% CI 0.47 to 0.93; 205 women) and a HR for overall survival of 0.70 (95% CI 0.50 to 0.98; 205 women). There was no difference in PFS whether fulvestrant was used in combination with another endocrine therapy or in the first- or second-line setting, when compared to control treatments: for monotherapy HR 0.97 (95% CI 0.90 to 1.04) versus HR 0.87 (95% CI 0.77 to 0.99) for combination therapy when compared to control, and HR 0.93 (95% CI 0.84 to 1.03) in the first-line setting and HR 0.96 (95% CI 0.88 to 1.04) in the second-line setting.Overall, there was no difference between fulvestrant and control treatments in clinical benefit rate (risk ratio (RR) 1.03, 95% CI 0.97 to 1.10; P = 0.29, I2 = 24%, 4105 women, 9 studies, high-quality evidence) or overall survival (HR 0.97, 95% CI 0.87 to 1.09, P = 0.62, I2 = 66%, 2480 women, 5 studies, high-quality evidence). There was no significant difference in vasomotor toxicity (RR 1.02, 95% CI 0.89 to 1.18, 3544 women, 8 studies, high-quality evidence), arthralgia (RR 0.96, 95% CI 0.86 to 1.09, 3244 women, 7 studies, high-quality evidence), and gynaecological toxicities (RR 1.22, 95% CI 0.94 to 1.57, 2848 women, 6 studies, high-quality evidence). Four studies reported quality of life, none of which reported a difference between the fulvestrant and control arms, though specific data were not presented.

Authors' conclusions: For postmenopausal women with advanced hormone-sensitive breast cancer, fulvestrant is at least as effective and safe as the comparator endocrine therapies in the included studies. However, fulvestrant may be potentially more effective than current therapies when given at 500 mg, though this higher dosage was used in only one of the nine studies included in the review. We saw no advantage with combination therapy, and fulvestrant was equally as effective as control therapies in both the first- and second-line setting. Our review demonstrates that fulvestrant is a safe and effective systemic therapy and can be considered as a valid option in the sequence of treatments for postmenopausal women with hormone-sensitive advanced breast cancer.

PubMed Disclaimer

Conflict of interest statement

CL: None to disclose associated with this review. Other, unrelated funding has been received from Novartis, Sanofi, Ipsen, Amgen, Roche (conference support) and honoraria from Roche. AG: Roche virtual ASCO 2015 and 2016 subscriptions. Advisory board for Novartis 2015. NW: Honoraria from Roche. On advisory boards for Novartis, Pfizer, Roche.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 Progression‐free survival, outcome: 1.1 Fulvestrant vs other endocrine therapy.
4
4
Forest plot of comparison: 2 Clinical benefit rate, outcome: 2.1 Fulvestrant vs other endocrine therapy.
5
5
Forest plot of comparison: 3 Overall survival, outcome: 3.1 Fulvestrant vs other endocrine therapy.
1.1
1.1. Analysis
Comparison 1 Progression‐free survival, Outcome 1 Fulvestrant vs other endocrine therapy.
1.2
1.2. Analysis
Comparison 1 Progression‐free survival, Outcome 2 First‐line vs second‐line or more.
1.3
1.3. Analysis
Comparison 1 Progression‐free survival, Outcome 3 Combination fulvestrant vs single agent with other endocrine therapy.
2.1
2.1. Analysis
Comparison 2 Clinical benefit rate, Outcome 1 Fulvestrant vs other endocrine therapy.
2.2
2.2. Analysis
Comparison 2 Clinical benefit rate, Outcome 2 Clinical benefit rate (first‐line vs second‐line).
2.3
2.3. Analysis
Comparison 2 Clinical benefit rate, Outcome 3 Combination vs monotherapy fulvestrant.
3.1
3.1. Analysis
Comparison 3 Overall survival, Outcome 1 Fulvestrant vs other endocrine therapy.
4.1
4.1. Analysis
Comparison 4 Toxicity, Outcome 1 Vasomotor.
4.2
4.2. Analysis
Comparison 4 Toxicity, Outcome 2 Arthralgia.
4.3
4.3. Analysis
Comparison 4 Toxicity, Outcome 3 Gynaecological.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

EFECT {published data only}
    1. Arnheim K. The EFECT study on endocrine therapy in advanced breast cancer: Fulvestrant fills therapeutic gap after failure of aromatase inhibitor. Onkologie 2007;30(3):148‐9.
    1. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double‐blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor‐positive, advanced breast cancer: Results from EFECT. Journal of Clinical Oncology 2008;26(10):1664‐70. - PubMed
    1. Ranganathan A, Moore Z, O'Shaughnessy JA. Phase III trial comparing fulvestrant with exemestane in patients with advanced breast cancer in whom previous nonsteroidal aromatase inhibitor therapy has failed. Clinical Breast Cancer 2007;7(6):446‐7.
FACT {published data only}
    1. Bergh J, Jonsson P, Lidbrink E, Trudeau M, Eiermann W, Brattstrom D, et al. First results from FACT ‐ an open‐label, randomized phase III study investigating loading dose of fulvestrant combined with anastrozole versus anastrozole at first relapse in hormone receptor positive breast cancer. Cancer Research. 2010; Vol. 69:24 Suppl.
    1. Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattstrom D, et al. FACT: An open‐label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first‐line therapy for patients with receptor‐positive postmenopausal breast cancer. Journal of Clinical Oncology 2012;30(16):1919‐25. - PubMed
    1. Henriksson R. FACT; Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy. PDQ 2006.
FIRST {published data only}
    1. Ellis MJ, Llombart A, Rolski J, Feltl D, Macpherson E, Lindemann J, et al. A comparison of high‐dose (HD, 500 mg) fulvestrant vs anastrozole (1 mg) as first‐line treatments for advanced breast cancer: Results from FIRST. Cancer Research. 2009; Vol. 69:(2 supplement, page 6126).
    1. Gottschalk N, Kuter I, Robertson JF, Ellis MJ, Lindeman J, Schrader I, et al. Safety and tolerability of fulvestrant high‐dose (500 mg) in postmenopausal women with hormone receptor positive advanced breast cancer. European Journal of Cancer, Supplement 2009;7(2‐3):284‐5.
    1. Lindemann JPO, Robertson JFR, Ellis MJ, Menu Y, Macpherson EJ, Ghiorghiu DDC. Independent central review of clinical benefit rates in FIRST: A phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first‐line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer. European Journal of Cancer, Supplement 2009;7(2‐3):282.
    1. Robertson JF, Llombart‐Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first‐line treatment for advanced breast cancer: results from the FIRST study. Journal of Clinical Oncology 2009;27(27):4530‐5. - PubMed
    1. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229‐38. - PubMed
Howell, Fulvestrant vs Anastrozole 2002 {published data only}
    1. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236‐9. - PubMed
    1. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment [see comments]. Journal of Clinical Oncology 2002;20(16):3396‐403. - PubMed
    1. Howell A, Robertson JFR, Vergote I, Mauriac L, Kleeberg UR, Quaresma Albano J, et al. Fulvestrant versus anastrozole for the treatment of advanced breast cancer: Survival analysis from a phase III trial. Proceedings of American Society of Clinical Oncology. 2003; Vol. 22:45.
    1. Vergote I. Survival analysis from a phase III trial of fulvestrant versus anastrozole [abstract]. European Journal of Cancer 2003;1:11.
Howell, Fulvestrant vs Tamoxifen 2004 {published data only}
    1. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double‐blind, randomized trial. Journal of Clinical Oncology 2004; Vol. 22, issue 9:1605‐13. - PubMed
    1. Makris A. A double‐blind, randomised, multicentre trial comparing the efficacy and tolerability of 250mg of Faslodex (long acting ICI 182,780) with 20mg of Nolvadex (tamoxifen) in postmenopausal women with advanced breast cancer. The National Research Register 1999.
Mehta 2012 {published data only}
    1. A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first‐line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. Clinical Advances in Hematology and Oncology 2012; Vol. 10:2; pages 14‐15.
    1. Mehta R. Phase III randomized study of anastrozole with or without fulvestrant as first‐line therapy in postmenopausal women with metastatic breast cancer. PDQ, SWOG‐S0226 2004.
    1. Mehta RS, Barlow WE, Albain KS, Vandenberg T, Dakhil SR, Tirumali NR, et al. A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first‐line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. Cancer Research. 2011; Vol. 71:(24 Suppl; abstract S1‐1).
    1. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. The New England Journal of Medicine 2012;367(5):435‐44. - PMC - PubMed
Osborne 2002 {published data only}
    1. Osborne CK. A double‐blind randomized trial comparing the efficacy and tolerability of faslodexTM (fulvestrant) with arimidexTM (anastrozole) in post‐menopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Research & Treatment. 2000; Vol. 64:1, page 27.
    1. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S. Double‐blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 2002;20(16):3386‐95. - PubMed
SoFEA {published data only}
    1. Correction to on behalf of the SoFEA investigators. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non‐steroidal aromatase inhibitors in postmenopausal patients with hormone‐receptor‐positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial [The Lancet Oncology 14, 989 (2013)]. The Lancet Oncology 2013; Vol. 14, issue 10:e391. - PubMed
    1. Johnston S. Phase III randomized study of fulvestrant with versus without anastrozole versus exemestane alone in postmenopausal women with estrogen receptor and/or progesterone receptor positive locally advanced or metastatic breast cancer that relapsed or progressed during prior treatment with nonsteroidal aromatase inhibitors. Physician Data Query (PDQ) 2005.
    1. Johnston S, Kilburn LS, Ellis P, Cameron D, Dodwell D, Howell A, et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non‐steroidal aromatase inhibitor ‐ first results of the SoFEA trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). European Journal of Cancer 2012;48(Suppl 3):S2.
    1. Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non‐steroidal aromatase inhibitors in postmenopausal patients with hormone‐receptor‐positive locally advanced or metastatic breast cancer (SoFEA): A composite, multicentre, phase 3 randomised trial. The Lancet Oncology 2013;14(10):989‐98. - PubMed
Xu 2011 {published data only}
    1. Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, et al. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: Results of a multicentre, double‐blind, randomised phase III trial. Cancer Chemotherapy and Pharmacology 2011;67(1):223‐30. - PubMed

References to studies excluded from this review

Carlson 2009 {published data only}
    1. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve S, Sledge G. Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. 2009 ASCO Annual Meeting. 2009; Vol. 27:15s (suppl; abstract 1013).
Carlson 2012 {published data only}
    1. Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Research and Treatment 2012;133(3):1049‐56. - PMC - PubMed
Perey 2007 {published data only}
    1. Perey L, Paridaens R, Hawle H, Zaman K, Nole F, Wildiers H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of Oncology 2007;18(1):64‐9. - PubMed

References to ongoing studies

NCT01602380 {published data only}
    1. NCT01602380. A global study to compare the effects of fulvestrant and Arimidex in a subset of patients with breast cancer. https://clinicaltrials.gov/ct2/show/NCT01602380 (accessed 13 November 2015).

Additional references

Al‐Mubarak 2013
    1. Al‐Mubarak M, Sacher AG, Ocana A, Vera‐Badillo F, Seruga B, Amir E. Fulvestrant for advanced breast cancer: a meta‐analysis. Cancer Treatment Reviews 2013;39(7):753‐8. - PubMed
Bundred 2005
    1. Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor‐positive advanced breast cancer. Cancer Investigation 2005;23(2):173‐81. - PubMed
Buzdar 1998
    1. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clinical Cancer Research 1998;4(3):527‐34. - PubMed
Cochran 1954
    1. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10(1):101‐29.
Cope 2013
    1. Cope S, Ouwens MJNM, Jansen JP, Schmid P. Progression‐free survival with fulvestrant 500 mg and alternative endocrine therapies as second‐line treatment for advanced breast cancer: A network meta‐analysis with parametric survival models. Value in Health 2013;16(2):403‐17. - PubMed
Di Leo 2010
    1. Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor‐positive advanced breast cancer. Journal of Clinical Oncology 2010;28(30):4594‐600. - PubMed
Di Leo 2012
    1. Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final analysis of overall survival for the Phase III CONFIRM trial: Fulvestrant 500 mg versus 250 mg. Cancer Research. 2012; Vol. 72:(24 suppl, page OT2).
Ferlay 2010
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893‐917. - PubMed
Flemming 2009
    1. Flemming J, Madarnas Y, Franek JA. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. Breast Cancer Research and Treatment 2009;115(2):255‐68. - PubMed
Gong 2014
    1. Gong DD, Man CF, Xu J, Fan Y. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta‐analysis of randomized controlled trials. Asian Pacific Journal of Cancer Prevention 2014;15(5):2095‐100. - PubMed
GRADEproGDT
    1. GRADEproGDT: GRADEpro Guideline Development Tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc). Available from www.gradepro.org.
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Pietras 2006
    1. Pietras RJ. Biologic basis of sequential and combination therapies for hormone‐responsive breast cancer. The Oncologist 2006;11(7):704‐17. - PubMed
RevMan 2012 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Tan 2013
    1. Tan PS, Haaland B, Montero AJ, Lopes G. Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta‐analysis. 2013 ASCO Annual Meeting. 2013; Vol. 31:(suppl; abstract e11591). - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. - PMC - PubMed
Valachis 2010
    1. Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta‐analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology 2010;73(3):220‐7. - PubMed
Wakeling 2000
    1. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocrine‐Related Cancer 2000;7(1):17‐28. - PubMed

MeSH terms

LinkOut - more resources